WASHINGTON – The novel low-density lipoprotein cholesterol–lowering agent evolocumab took day 1 of the annual meeting of the American College of Cardiology by storm on the strength of three...

Field of Interest: Cardiology

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

randomness